Steve Lin, MD
Interventional Cardiology · Lexington, KYNPI 1518979111
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $319,450 of the $362,339 with a category attached, or 88.2%. Novo Nordisk accounts for 69.2% of it on its own, with 46 other manufacturers making up the rest. Among interventional cardiology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 875 payments — averaging $414.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$251K
- Boehringer Ingelheim$40K
- Johnson & Johnson$28K
- Lilly USA, LLC$15K
- AstraZeneca$10K
- Scpharmaceuticals Inc.$5K
- plus $15K from 41 others
Across 3 payments — averaging $3241.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10K
What the payments were for
- Consulting fees$5,1501%
- Speaking & faculty fees$319,45088%
- Travel & lodging$19,4545%
- Food & beverage$18,0125%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$68,620
- JARDIANCE$53,743
- Ozempic$51,366
- RYBELSUS$27,858
- XARELTO$26,323
- FUROSCIX$4,621
- LOKELMA$4,386
- Indigo System$4,201
- FARXIGA$4,131
- Impella$1,124
- ONYX FRONTIER$927
- Navicross$843
- Indigo$314
- CAMZYOS$249
- Resolute$188
- FlowTriever$171
- ClotTriever$171
- CARDIOMEMS$143
- PANTHERIS$134
- Vascepa$114
How this compares
$362,339 in reported general payments places this provider in the 95th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 452 | $463,173 |
| OzempicSemaglutide | 388 | $439,753 |
| EliquisApixaban | 408 | $423,255 |
| EntrestoSacubitril/Valsartan | 345 | $382,601 |
| JardianceEmpagliflozin | 392 | $380,425 |
| FarxigaDapagliflozin Propanediol | 316 | $246,865 |
| WegovySemaglutide | 82 | $109,045 |
| KerendiaFinerenone | 99 | $100,421 |
| Repatha SureclickEvolocumab | 86 | $95,767 |
| BrilintaTicagrelor | 35 | $38,115 |
| CorlanorIvabradine Hcl | 47 | $34,543 |
| NexlizetBempedoic Acid/Ezetimibe | 47 | $31,017 |
| Praluent PenAlirocumab | 23 | $21,111 |
| VascepaIcosapent Ethyl | 34 | $17,905 |
| VerquvoVericiguat | 21 | $14,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $250,596 | $548,799470 claims |
| Johnson & JohnsonXarelto | $27,728 | $463,173452 claims |
| PfizerEliquis | $697 | $423,255408 claims |
| NovartisEntresto | $754 | $382,601345 claims |
| Boehringer IngelheimJardiance | $40,452 | $380,425392 claims |
| AstraZenecaFarxiga, Brilinta | $9,615 | $284,980351 claims |
| BayerKerendia | $117 | $100,42199 claims |
| AmgenCorlanor | $399 | $34,54347 claims |
| Esperion Therapeutics, Inc.Nexlizet | $95 | $31,01747 claims |
| MerckVerquvo | $308 | $14,76221 claims |
| Lilly USA, LLCMounjaro | $14,688 | $12,43212 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $45 | $12,07220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Lexington
- Avichai EresLexington$616K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Armaghan SoomroLexington$117K
- Adrian MesserliLexington$41K
- Hussam HamdallaLexington$24K
- Henry Charles RichmondLexington$20K
- Michael ShihLexington$20K
- Mubashir QaziLexington$18K
- Michael RukavinaLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.